OKT3

DRUG5 trials

Sponsors

National Cancer Institute (NCI), Hadassah Medical Organization, St. Jude Children's Research Hospital

Conditions

HealthyHematologic MalignanciesKidney NeoplasmsMelanomaNonalcoholic Steatohepatitis

Phase 1

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

TerminatedNCT00091611

National Cancer Institute (NCI)Kidney Neoplasms

Start: 2004-09-30End: 2008-03-31Updated: 2012-10-26

Oral OKT3 in Combination With Beta-D-Glucosylceramide

Hadassah Medical OrganizationHealthy

Start: 2008-01-31End: 2008-06-30Target: 20Updated: 2009-02-04

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

CompletedNCT00824135

St. Jude Children's Research HospitalHematologic Malignancies

Start: 2009-01-31End: 2016-12-31Updated: 2017-01-02

Phase 2

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

CompletedNCT00080353

National Cancer Institute (NCI)Melanoma

Start: 2004-03-31End: 2008-12-31Updated: 2012-06-14

Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome

CompletedNCT01205087

Hadassah Medical OrganizationNonalcoholic Steatohepatitis

Start: 2010-09-30End: 2011-04-30Target: 36Updated: 2011-06-23

Related Papers

Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms

Journal of Pediatric Hematology/Oncology2018-05-105 citations